http://www.beIgraviacentre.com/blog...y-validated-fgf5-inhibitor-hair-loss-product/
"Objective, independent clinical trials of évolis ONE were carried out on 32 otherwise healthy individuals, aged between 31 and 55, with androgenetic alopecia. Men taking part measured between 2 and 4 on the Norwood scale, whilst female subjects registered I-2 to II-2 on the Ludwig scale of hair loss. The trials lasted 112 days (16 weeks) and products were applied twice daily. Gravimetric Determination methods were used to analyse the impact of évolis ONE in reducing genetic hair loss over 112 days (16 weeks) with twice daily use. Findings showed this resulted in an 80.2% reduction in hair loss. When testing the ‘hair differentiation’ – the ratio of growing (anagen) hairs to resting (telogen) hair follicles – results gathered based on the Van Scott “hair pluck” method found an anagen increase of 44.2% over the same period . PhotoGrammetrix™3 measurements, a form of visual assessment using scientific photographs, used to gauge the general improvement in hair quality and volume showed an increase of 143.3%. This visual evaluation was reportedly conducted by AMA’s Institutional Review Board. A 51 subject Repeat Insult Patch Test (RIPT) exploring skin irritation and sensitisation was also carried out by AMA Laboratories and was said to result in a “zero adverse event” report. However, évolis warns users that those ‘who suffer from a skin condition such as eczema, psoriasis or sensitive skin may experience irritation and/or a dry, itchy scalp’ and advises them to carry out a patch test first to assess their sensitivity. - See more at: http://www.beIgraviacentre.com/blog...bitor-hair-loss-product/#sthash.QL0dsrve.dpuf"
